Keyphrases
Adverse Event Reporting System
100%
Tumour Necrosis Factor Inhibitor (TNFi)
100%
T-cell non-Hodgkin Lymphoma
100%
Thiopurines
60%
Confidence Interval
20%
Inflammatory Bowel Disease
20%
MEDLINE
20%
Surveillance Epidemiology
13%
Azathioprine/6-mercaptopurine
13%
Hepatosplenic T-cell Lymphoma
13%
Etanercept
6%
Rheumatoid Arthritis
6%
Infliximab
6%
Adalimumab
6%
Psoriasis
6%
Lymphoma
6%
Non-Hodgkin Lymphoma
6%
Cyclosporine
6%
Ulcerative Colitis
6%
Crohn's Disease
6%
Nineteen
6%
Fisher's Exact Test
6%
Histological Subtypes
6%
Methotrexate
6%
Immunomodulator
6%
Inflammatory Diseases
6%
Ankylosing Spondylitis
6%
Mycosis Fungoides
6%
Certolizumab
6%
Concomitant Use
6%
Leflunomide
6%
Approved Indication
6%
Aminosalicylates
6%
Sézary Syndrome
6%
Freedom of Information
6%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
100%
Nonhodgkin Lymphoma
100%
Tumor Necrosis Factor Inhibitor
100%
Mercaptopurine
73%
Inflammatory Bowel Disease
20%
Azathioprine
13%
T Cell Lymphoma
13%
Infliximab
6%
Rheumatoid Arthritis
6%
Etanercept
6%
Adalimumab
6%
Ciclosporin
6%
Methotrexate
6%
Immunomodulating Agent
6%
Ulcerative Colitis
6%
Crohn's Disease
6%
Psoriasis
6%
Inflammatory Disease
6%
Aminosalicylic Acid
6%
Mycosis fungoides
6%
Leflunomide
6%
Ankylosing Spondylitis
6%
Sezary Syndrome
6%
Inflammatory Arthritis
6%